NUCRYST Announces First Quarter 2008 Financi...(r ended December 31 2007 and in our Quar...),Health

Date:5/6/2008

r ended December 31, 2007 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov and with securities authorities in Canada on SEDAR at http://www.sedar.com. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and NUCRYST disclaims any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future developments or otherwise after the date hereof.

NUCRYST PHARMACEUTICALS CORP.

Financial Highlights

(unaudited)

(thousands of U.S. dollars except share and per share data)

-------------------------------------------------------------------------

Three Months Ended March 31

----------------------------

Condensed Consolidated Statements of

Operations 2008 2007

-------------------------------------------------------------------------

Revenue $ 5,189 $ 5,234

Loss from operations (2,886) (1,845)

Net loss (2,180) (1,864)

Net loss per common share

- basic (0.12) (0.10)

- diluted (0.12) (0.10)

Weighted average number of common shares

outstanding

- basic 18,370,092 18,311,962

- diluted 18,370,092 18,311,962

-------------------------------------------------------------------------

'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. NUCRYST Announces Management Realignment and R&D Portfolio Change
2. NUCRYST Announces Senior Management Change
3. NUCRYST Pharmaceuticals announces year-end results
4. NUCRYST Pharmaceuticals announces 2007 third quarter results
5. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
6. NUCRYST and Smith & Nephew Revise Agreements
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Bank of America Healthcare Conference
8. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
9. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
10. Rigel Announces First Quarter 2008 Financial Results
11. BioForm Medical Announces Extension of Lock-Up Period